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accepted JulIf you always do what you always did, you will
always get what you always got
dAlbert Einstein (1)Four decades ago, we believed in a dogma that acute
myocardial infarction (MI) resulted from near total
luminal obstruction by progressive thickening of coro-
nary atheroma. At that time, pathologists used to report
cross-sectional area (CSA) stenosis for the quantiﬁcation
of disease, and thrombosis was considered the conse-
quence and not the cause of MI (2). Only after the
description of plaque remodeling (3), did it become clear
that quantiﬁcation by CSA overestimated disease when
compared with angiography; for instance, a 75% CSA
stenosis was only a 50% (diameter) stenosis in a coronary
angiogram. Expanding the concept further, the study of
Ambrose et al. (4) demonstrated that progression of
coronary artery disease (CAD) to MI occurred predom-
inantly in nonobstructive lesions. Narula et al. (5) have
recently explained that the majority of the fateful
lesions may substantially enlarge over time before plaque
rupture, as previously observed in aortic plaques (6),
reconciling the discrepancy between the reports of pre-
ceding nonobstructive lesions and signiﬁcant luminal
stenosis at the time of the acute event. Intravascular
imaging studies have indeed demonstrated that the
lesions likely to result in a major adverse coronary event
(MACE) have modest luminal stenosis, large plaque
burden, and thin ﬁbrous caps, but evolve voluminously to
result in signiﬁcant stenosis at the time of the acute event
(7). It has become increasingly clear that regardless of the
initial luminal stenosis, the evolving plaque burden and
attenuated ﬁbrous cap comprise the major determinants
of plaque rupture in patients with acute coronary
syndromes (ACS) (5–7); most plaques at the time of
rupture are huge and signiﬁcantly obstructive. On the
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y 29, 2013.ﬁbrotic, lesions may be associated with angina and the
need for revascularization. As such, ﬁbrotic lesions not
result in ACS. Therefore, increasing plaque burden
and luminal stenosis predispose to both ACS as well as
angina requiring revascularization. As such, the main
determinant of atherothrombosis progression is plaque
composition. Hence, plaque characterization should
enhance risk stratiﬁcation beyond coronary angiography or
physiological testing. It is therefore prudent to ask whether
fractional ﬂow reserve (FFR) with intravascular imaging
would be superior to FFR alone?
Lessons From Patients With Chronic Stable Angina:
Courage, FAME II, and the Role of FFR
Multiple randomized trials in patients with chronic stable
angina comparing percutaneous coronary intervention
(PCI) versus surgical revascularization established a 5-year
event rate of 16.9% and 16.7%, respectively (8). The
COURAGE (Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation) trial documented no
difference between optimal medical therapy (OMT) and
OMT þ PCI at higher event rates of 20% and 19.5%,
respectively (9), and proposed a powerful concept, that is,
not every lesion obstructive by angiography needs to be
revascularized.
It became clear that symptomatic patients with multivessel
CAD needed better risk stratiﬁcation, and FFR was tested
prospectively in the FAME (Fractional Flow Reserve Versus
Angiography for Guiding PCI in Patients With Multivessel
Coronary Artery Disease) trial (10). The study identiﬁed that
37% of lesions morphologically obstructive by angiography
were FFR negative. Avoiding PCI in these (less critically
stenotic) lesions resulted in a 5% absolute reduction in death,
nonfatal MI, and repeat revascularization at 1 year (10).
Therefore, exclusion of FFR-negative lesions allowed for
selection of the subset of patients who might truly beneﬁt
from PCI. In the logical extension of this strategy, the
randomized FAME II trial compared OMT and OMT +
PCI in the FFR-positive lesions. OMT + PCI emerged
superior when compared with OMT alone in FFR-positive
lesions. However, the events were primarily driven by
urgent revascularization (1.6% vs. 11.1%; p < 0.0001)
without a difference in death orMI (11). The number needed
Figure 1 Why Imaging Can Risk Stratify CAD Beyond Angiography and FFR
This ﬁgure illustrates 3 different risk levels for coronary atherosclerosis at 3 different levels of stenosis. (Upper row) Highest risk (A to C): ruptured plaques. Please notice that
lipid-rich plaques can precipitate fatal coronary thrombosis at different degrees of stenosis, including: mild (A), moderate (B), and severe (C). However, all 3 lethal plaques
share the same composition, that is, lipid-rich, thin ﬁbrous cap. Coronary angiography and fractional ﬂow reserve (FFR) can only identify the severely stenotic plaque, and
therefore miss the mildly and moderately obstructive. However, intravascular imaging will identify all 3. (Middle row) Intermediate risk (D to F): thin-cap ﬁbroatheromas. As
illustrated in thrombotic plaques, only intravascular imaging will correctly identify all 3 plaques as high risk, independent from the degree of stenosis. (Lower row) Lowest risk
(G to I): ﬁbrotic plaques. Again, all 3 stable plaques can be properly identiﬁed by imaging. However, coronary angiography and FFR will identify the severely stenotic plaque (I).
Furthermore, this lesion will be classiﬁed as high risk. However, severely stenotic, ﬁbrotic plaques may be just a marker for advanced disease but will not evolve with plaque
rupture and thrombosis. (See text for details). CAD ¼ coronary artery disease; NC ¼ necrotic core; TCFA ¼ thin-cap ﬁbroatheroma; Thr ¼ thrombus. Adapted with permission
from Narula et al. (5).
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intervention to prevent 1 episode of revascularization.Lessons From Patients With ACS:
PROSPECT, VIVA, PREDICT, and the
Role of Intracoronary Imaging
ACS patients are at risk of recurrent coronary events from
the progression of nonculprit lesions (NCL). Contrary to the
COURAGE and FAME II trials in patients with stable
angina, studies in ACS successfully treated all culprit and
angiographically obstructive lesions before evaluating NCL
by intravascular imaging. Hence, the role of obstructive
disease in triggering future events was eliminated from
the beginning. In the PROSPECT (Providing Regional
Observations to Study Predictors of Events in the Coronary
Tree) study (7), the average percent diameter stenosis for
NCL responsible for future coronary events (the high-risk
plaque) at 3.4 years was 32  21%; almost all NCLtriggering future coronary events were <70% diameter
stenosis, similar to the original proposal of the Ambrose-
Fuster study (4). However, at the time of the subsequent
event, these NCL had expanded to 65  16% luminal
diameter stenosis. Therefore, a high-risk plaque can
precipitate plaque rupture and thrombosis at a wide range of
angiographic stenoses, from mild to severe, as documented
in the PROSPECT trial, and illustrated in Figure 1.
When analyzing morphological features, plaque burden
emerged as the strongest independent predictor for clinical
events (hazard ratio 5), along with virtual histology intra-
vascular ultrasound–veriﬁed thin-cap ﬁbroatheroma, and
a minimal luminal area 4 mm2 (7). Simultaneous presence
of these 3 parameters was associated with an 18% incidence
of future MACE at 3.4 years (hazard ratio: 11.5) (7).
Such high-risk plaques were rare, present in only 4.2% of
all plaques studied (12). Although most plaques were not
critically occlusive to start with, they expanded substantially
in the interim, and evolved to demonstrate large cross-
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studies, conﬁrming the plaque expansion hypothesis of
Narula et al. (5). Two additional imaging studies, the
VIVA (VH-IVUS in Vulnerable Atherosclerosis) and the
PREDICTION (Prediction of Progression of Coronary
Artery Disease and Clinical Outcome Using Vascular Pro-
ﬁling of Shear Stress and Wall Morphology) trials also
identiﬁed plaque burden >70% as a powerful independent
predictor (13,14). Finally, the Motoyama et al. (15) study
identiﬁed low attenuated and positively remodeled, large,
nonobstructive plaques by computed tomographic
angiography to be associated with a 22.5% risk of
developing ACS after 2 years. As reported in the
PROSPECT trial, the incidence of these high-risk plaques
was only 4.5%. Most importantly, low attenuated plaques
were amenable to reductions in plaque volume after statin
therapy (16).
Integrating FFR With Intravascular Imaging
for the Prediction of Events
Before the FAME II study, obstructive lesions by angiog-
raphy could be treated by OMT with or without revascu-
larization. After FAME II, functional evaluation of these
lesions has become the unwritten standard of management.
If the lesion is FFR-negative, OMT may be the best option,
and PCI may not improve an event-free survival. However,
if the lesion is FFR-positive, PCI is indicated, and is
expected to obviate the need for urgent revascularization.
What may happen if an FFR-positive lesion is left for
OMT alone? The FAME II–based penalty may be the need
for urgent revascularization in the short term. However, the
data are evolving that the obstructive lesions may eventually
lead to death and MI (17). On the other hand, not necessary
all FFR-positive lesions will beneﬁt from revascularization.
As stated earlier, <15% of FFR-positive lesions lead to car-
diovascular (CV) events. OMT alone can reduce ischemic
burden and improve prognosis (18), and FFR-positive lesions
may still be suitable for regression. This was the rationale for
the recently reported YELLOW (Reduction in Yellow Pla-
que by Aggressive Lipid-Lowering Therapy) trial (19), which
randomized patients with multivessel CAD and stable angina
to high-dose rosuvastatin 40 mg versus standard of care statin
therapy. After successful PCI of culprit lesions, the remaining
obstructive, FFR-positive, NCL was evaluated by near
infrared spectroscopy and intravascular ultrasound. The
primary objective was reduction in lipid content. The study
was not powered for clinical events. After 7 weeks of therapy,
lesions randomized to the intensive group showed a signiﬁ-
cant reduction in lipid content. Of potential clinical value,
large regression in lipid plaques also showed a trend towards
improvement in FFR (19). The YELLOW trial provided
evidence that aggressive statin therapy can induce regression
in lipid-rich plaques, even when FFR-positive and severely
obstructive by angiography. Importantly, no change was
observed in the lipid content (and FFR) by either therapy ifthe plaque was ﬁbrous to begin with. These plaques may not
harbor an increased risk of plaque rupture and thrombosis.
Therefore, it is conceivable that risk stratiﬁcation would
improve over and above quantitative assessment by using
qualitative assessment of the plaque outside the lumen.
Optimal imaging quality obtained by optical coherence
tomography studies demonstrate the ability to detect mu-
ltiple, complex coronary plaques in high-risk patients, and
may evolve to be the gold standard for quantiﬁcation of the
ﬁbrous cap in vivo. However, despite the image quality,
outcome research in OCT is scarce and needs to fulﬁll these
expectations (20). High-dose statins and further improve-
ments in medical therapy, including PCSK9 antibodies,
harbor great potential to further reduce future events (21). For
high-risk plaques, signiﬁcant reductions in lipid may poten-
tially be the ﬁrst step for improvements in ﬂow (19).
Conversely, lack of regression may reﬂect impending
progression to clinical events. Similarly, ﬁbrotic lesions may
be properly treated by OMT, and are least likely to result in
ACS.However, if clinically refractory to OMT, PCI could be
offered at a later date.
Although FFR is a useful tool to guide clinicians in
clinical practice, is it safe to leave all FFR-negative, but
angiographically severe, lesions without revascularization?
Not really. At least 3% of FFR-negative lesions in the
FAME study resulted in MACE at 2 years. Most impor-
tantly, the beneﬁt of FFR-guided PCI lost statistical
signiﬁcance when compared with angiographic-guided PCI
at 2 years (p ¼ 0.08) (22). For nonobstructive disease, the
PROSPECT study demonstrated that despite the OMT,
11.6% of lesions developed MACE. Because they were less
stenotic, a longer period was needed to develop adverse
events. Plaque composition played a major role, with only
0.7% MACE at 3 years for ﬁbrotic lesions compared with
2.7% for lipid-rich ﬁbroatheromas (p < 0.0001) (23).
The Motoyama et al. (15) study of CT angiography
demonstrated that the larger the plaque burden and greater
the necrotic core, the earlier and higher the likelihood of
an adverse event. The evidence is clear that FFR will
identify lesions at risk to develop MACE earlier. However,
loss of statistical power after 2 years suggests that longer
follow-up may show angiography-driven and FFR-driven
curves converging with similar event rates.
The ﬁeld of high-risk atheroma and prevention of MACE
is evolving rapidly. After consideration of the aforemen-
tioned trials, 2 important issues remain disturbing, and
deserve future investigation. First, the evolution of NCL to
an eventful state is not clear. Second, the MACE that occur
in asymptomatic subjects before reaching any medical
attention are not beneﬁciary of the research directed at the
imaging or hemodynamic signiﬁcance.
Conclusions
Current analyses in patients with presumably stable angina
suggest that FFR-guided PCI will reduce short-term
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long term, some of these lesions may develop major events,
including death and MI. Although FFR was an improve-
ment over angiography, only a few of the FFR-positive,
obstructive lesions were associated with CV events. In this
group, FFR could not separate between high-risk
and relatively benign lesions. Intravascular imaging can see
beyond luminal obstruction, and may represent the next
frontier to risk stratify these patients. At the same time,
contemporary analyses in patients with ACS demonstrate
that most recurrent events arise from positively remodeled
plaques with a large atherosclerotic burden, which may not
necessarily be obstructive by angiography at that time. FFR
has little role in the setting of nonobstructive disease, and
may even misclassify these lesions. Imaging may be the only
way to detect and characterize high-risk, nonobstructive
disease. Current and promising aggressive medical therapies
could help avoid expansion of such lipid-rich plaques, and
the refractory lesions may be deserving of revascularization.
Angiographic, physiological, and imaging data are com-
plementary and synergistic in the search for preventing
future MACE. Elucidating the expansive process preceding
ACS may be fundamental to get there. However, from
nonobstructive to thrombotic plaques, the lumen itself is
predominately an innocent bystander. Thinking out of the
lumen is fundamental, now more than ever.
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